MedTrace Logo

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

NCT01637285 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2015-07-31

No results posted yet for this study

Summary

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Conditions

  • Healthy

Interventions

BIOLOGICAL

PF-04856883

Dose A

BIOLOGICAL

PF-04856883

Dose B

BIOLOGICAL

PF-04856883

Dose C

BIOLOGICAL

PF-04856883

Dose D

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01637285 on ClinicalTrials.gov